Suppr超能文献

[激肽释放酶-激肽系统作为糖尿病视网膜病变治疗的靶点]

[Kallikrein-kinin system as a target for diabetic retinopathy treatment].

作者信息

Iarovaia G A, Neshkova E A, Blokhina T B, Kochergin S A, Vorob'eva I V, Gigineishvili D N

出版信息

Vestn Oftalmol. 2012 Jul-Aug;128(4):78-81.

Abstract

Multifactor etiology of diabetic retinopathy (DR) determines difficulty of understanding of pathogenesis and need of search of effective approaches to study key mechanisms of development of this microvascular complication of diabetes mellitus (DM). Significant achievements of the last years show the contribution of two proteolytic systems into pathogenesis of DR, that control vascular tone and permeability - kallikrein-kinin (KKS) and renin-angiotensin systems (RAS). Among new approaches to DR treatment one of the most appropriate is an influence on KKS by means of inhibiting kallikrein, that leads to reduction of retinal vascular permeability and allows to prevent the development of macula oedema and other consequences of vascular wall damage in DR.

摘要

糖尿病视网膜病变(DR)的多因素病因决定了理解其发病机制的难度,以及寻找有效方法来研究糖尿病(DM)这种微血管并发症发展关键机制的必要性。过去几年的重大进展表明,两种蛋白水解系统在DR发病机制中发挥了作用,它们控制血管张力和通透性——激肽释放酶-激肽系统(KKS)和肾素-血管紧张素系统(RAS)。在DR治疗的新方法中,最合适的方法之一是通过抑制激肽释放酶来影响KKS,这会降低视网膜血管通透性,并有助于预防黄斑水肿的发展以及DR中血管壁损伤的其他后果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验